MyFinsight
Home
Blog
About
Contact
Download
Download image
US
$1,731,222K
Europe
$405,899K
Non USOr Europe
$176,715K
Europe
$79,429K
US
$62,126K
Non USOr Europe
$31,234K
US
$205,715K
Europe
$77,715K
Non USOr Europe
$25,057K
Europe
$88,049K
US
$68,467K
Non USOr Europe
$34,921K
Amvuttra
$2,313,836K
ONPATTRO
$172,789K
GIVLAARI
$308,487K
OXLUMO
$191,437K
TTR
$2,486,625K
Rare
$499,924K
Roche
$394,881K
Regeneron
Pharmaceuticals Incorporation
$113,957K
Other Collaborations
$44,528K
Product
$2,986,549K
Collaborations
$553,366K
Royalty
$174,022K
Total revenues
$3,713,937K
Income (loss) from
operations
$501,578K
Total operating costs
and expenses
$3,212,359K
Income (loss) before
income taxes
$323,152K
Foreign currency
translation gains (losses)
$11,624K
Unrealized gains (losses)
on marketable...
$1,816K
Defined benefit pension
plans, net of tax
-$981K
Total other expense,
net
-$178,426K
Interest income
$111,470K
Research and development
$1,319,775K
Selling, general and
administrative
$1,210,713K
Cost of goods sold
$677,166K
Cost of
collaborations and royalties
$4,705K
Other income
(expense), net
$5,204K
Net income (loss)
$313,747K
Net other
comprehensive loss
$14,421K
(provision for) benefit
from income taxes
$9,405K
Interest expense
$252,627K
Loss related to
convertible debt
$42,473K
Comprehensive income (loss)
$328,168K
Back
Back
Income Statement
source: myfinsight.com
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)